Merck reported positive results for its experimental treatment designed to protect infants from RSV. The mid to late-stage trial showed the treatment reduced RSV-related hospitalizations by over 80% and lower respiratory infections by 90% compared to a placebo in infants through five months. The treatment also reduced lower respiratory infections requiring medical attention by more than 60%. Merck plans to discuss the data with regulators, aiming for availability by the 2025 to 2026 RSV season.
Category
đź—ž
NewsTranscript
00:00It's Benzinga, bringing Wall Street to Main Street.
00:02Merck reported positive results for its experimental treatment designed to protect
00:06infants from RSV. The mid- to late-stage trial showed the treatment reduced RSV-related
00:11hospitalizations by over 80% and lower respiratory infections by 90% compared to a placebo in infants
00:17through first five months. The treatment also reduced lower respiratory infections requiring
00:22medical attention by more than 60%. Merck plans to discuss the data with regulators,
00:27aiming for availability by the 2025-2026 RSV season.
00:31For all things money, visit Benzinga.com slash GSTV.